Caspase inhibitors as neuroprotective agents

Emerging Drugs

Volumn 6, Issue 1, 2001, Pages 81-94

  Legos, J J ^a   Lee, D ^a   Erhardt, J A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Apoptosis; Caspase; Caspase inhibitors; Spinal cord injury; Stroke; Traumatic brain injury

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; 4 AMINOPYRIDINE; ACETYLTYROSYLVALYLALANYLASPARTYL CHLOROMETHYLKETONE; APTIGANEL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BMS 204356; CASPASE; CASPASE INHIBITOR; CATHEPSIN B; CM 101; CV 1013; DISUFENTON SODIUM; DIZOCILPINE; ELIPRODIL; FLUNARIZINE; FOSPHENYTOIN SODIUM; GAVESTINEL; IDN 5370; IS 4; L 826791; LUBELUZOLE; NEUTROPHIL INHIBITORY FACTOR; NIMODIPINE; PRALNACASAN; PROTEIN KINASE; SIPATRIGINE; TISSUE PLASMINOGEN ACTIVATOR; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZICOTINIMIDE;

APOPTOSIS; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE FUNCTION; NEUROPROTECTION; NONHUMAN; REVIEW; SPINAL CORD INJURY;

EID: 0035037123     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.1.81     Document Type: Review

References (88)

1. Neuroprotection by the inhibition of apoptosis
2. Caspases as treatment targets in stroke and neurodegenerative diseases
3. Caspases and caspase inhibitors
4. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches
5. Acute stroke therapy: Translating preclinical neuroprotection to therapeutic reality
6. Current status of neuroprotection trials for traumatic brain injury: Lessons from animal models and clinical studies
7. Rising stroke rates spur efforts to identify risks, prevent disease
8. Further evolution toward effective therapy for acute ischemic stroke
9. Emerging therapeutic targets in focal stroke and brain trauma: Cytokines and the brain inflammatory response to injury
10. Head and spinal cord injury
11. Spinal cord injury. An overview
12. Traumatic brain injury
13. The Second National Acute Spinal Cord Injury Study
14. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study
15. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study
16. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study
17. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial
18. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats
19. The two-edged sword of large-dose steroids for spinal cord trauma
20. Consequences of high-dose steroid therapy for acute spinal cord injury
21. High dose methylprednisolone in the management of acute spinal cord Injury - A systematic review from a clinical perspective
22. Mannitol for acute traumatic brain injury
23. Public perception of stroke warning signs and knowledge of potential risk factors
24. The most unkindest cut of all: On the multiple roles of mammalian caspases
25. Caspases: Enemies within
26. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme
27. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis
28. Substrate specificities of caspase family proteases
29. Interleukin-18 and interleukin-1 beta: Two cytokine substrates for ICE (caspase-1)
30. Therapeutic potential of anti-inflammatory drugs in focal stroke
31. Recent advances in neurotrauma
32. Neuronal death after brain injury. Models, mechanisms and therapeutic strategies in vivo
33. Advances in secondary spinal cord injury: Role of apoptosis
34. Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury
35. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury
36. Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury
37. Caspase-3 mediated neuronal death after traumatic brain injury in rats
38. Cytochrome c release and caspase activation in traumatic axonal injury
39. Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade
40. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys
41. Apoptosis after traumatic human spinal cord injury
42. Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury
43. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury
44. Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat
45. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation
46. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia
47. Survival- and death-promoting events after transient cerebral ischemia: Phosphorylation of Akt, release of cytochrome c and Activation of caspase-like proteases
48. Expression of a dominant negative mutant of interleukin-1-beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury
49. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia
50. Interleukin-1 beta mRNA expression in ischemic rat cortex
51. Quantitative changes in interleukin proteins following focal stroke in the rat
52. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat
53. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage
54. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia
55. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat
56. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain
57. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat
58. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice
59. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus
60. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines
61. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage
62. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family
63. Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo
64. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat
65. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality
66. Selective inhibitors of apoptotic cascades: Implications for novel therapeutic strategies
67. Critical role for caspase-3/-7 in PC12 cell death following trophic factor deprivation established through use of novel caspase inhibitor
68. A caspase-3 selective inhibitor, L-826,791 reduces brain injury without altering limbic seizure activity mediated by kainate-induced excitotoxicity
69. Caspase inhibitors for the treatment of acute, life-threatening degenerative diseases
70. CV-1013, a novel, potent and irreversible pan-caspase inhibitor with activity in animal models of hepatitis, stroke and myocardial infarction
71. Peptidomimetic caspase inhibitors with neuroprotective activity in vitro and in vivo
72. Role of inhibition of caspase activity, processing and caspase substrate cleavage in the survival of apoptotic cortical and sympathetic neurons by the caspase inhibitor IDN5370 (CGP82630)
73. An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage
74. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury
75. Caspases determine the vulnerability of oligodendrocytes in the ischemic brain
76. Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice
77. Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia
78. Non-specific effects of methyl ketone peptide inhibitors of caspases
79. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity
80. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates
81. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis
82. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model
83. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
84. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease
85. Wild-type but not Parkinson's disease-related Ala-53 - > Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli
86. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain
87. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
88. Recommendations for standards regarding preclinical neuroprotective and restorative drug development